155 related articles for article (PubMed ID: 2470592)
41. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
42. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
43. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
44. Effect of somatostatin analogue octreotide injected into the third cerebral ventricle on pentagastrin-induced gastric acid secretion in rats.
Gao F; Hu XF
World J Gastroenterol; 2006 May; 12(17):2767-9. PubMed ID: 16718766
[TBL] [Abstract][Full Text] [Related]
45. Flush symptoms caused by a mesenteric carcinoid without liver metastases.
Sonnet S; Wiesner W
JBR-BTR; 2002; 85(5):254-6. PubMed ID: 12463502
[TBL] [Abstract][Full Text] [Related]
46. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
47. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue.
Whitehouse I; Beglinger C; Rüttimann G; Gyr K
Gut; 1986 Feb; 27(2):141-6. PubMed ID: 2868973
[TBL] [Abstract][Full Text] [Related]
49. Effect of thiorphan on response of the guinea-pig gallbladder to tachykinins.
Maggi CA; Patacchini R; Renzi D; Santicioli P; Regoli D; Rovero P; Drapeau G; Surrenti C; Meli A
Eur J Pharmacol; 1989 Jun; 165(1):51-61. PubMed ID: 2475353
[TBL] [Abstract][Full Text] [Related]
50. Distinguishing features of idiopathic flushing and carcinoid syndrome.
Aldrich LB; Moattari AR; Vinik AI
Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
[TBL] [Abstract][Full Text] [Related]
51. Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.
Mazzone SB; Geraghty DP
Br J Pharmacol; 2000 Mar; 129(6):1121-31. PubMed ID: 10725260
[TBL] [Abstract][Full Text] [Related]
52. Flushing in the carcinoid syndrome and plasma kallikrein.
Lucas KJ; Feldman JM
Cancer; 1986 Nov; 58(10):2290-3. PubMed ID: 2428458
[TBL] [Abstract][Full Text] [Related]
53. Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.
Wiedenmann B; Räth U; Rädsch R; Becker F; Kommerell B
Klin Wochenschr; 1988 Jan; 66(2):75-7. PubMed ID: 2894481
[TBL] [Abstract][Full Text] [Related]
54. Bronchoconstrictor and hypotensive effects in relation to pharmacokinetics of tachykinins in the guinea-pig--evidence for extraneuronal cleavage of neuropeptide K to neurokinin A.
Martling CR; Theodorsson-Norheim E; Norheim I; Lundberg JM
Naunyn Schmiedebergs Arch Pharmacol; 1987 Aug; 336(2):183-9. PubMed ID: 2825041
[TBL] [Abstract][Full Text] [Related]
55. Carcinoid syndrome.
Zambrzycki JK; Elliott CG
Nurse Anesth; 1993 Dec; 4(4):198-201. PubMed ID: 7907889
[TBL] [Abstract][Full Text] [Related]
56. Tachykinins (substance P, neurokinin A, neuropeptide K, and neurokinin B) in the cerebral circulation: vasomotor responses in vitro and in situ.
Jansen I; Alafaci C; McCulloch J; Uddman R; Edvinsson L
J Cereb Blood Flow Metab; 1991 Jul; 11(4):567-75. PubMed ID: 1711051
[TBL] [Abstract][Full Text] [Related]
57. The pentagastrin test as an indicator of a cure in surgically treated patients with advanced carcinoid disease.
Ahlman H; Nilsson O; Dahlström A; Tisell LE
J Surg Oncol; 1988 May; 38(1):52-6. PubMed ID: 2453757
[TBL] [Abstract][Full Text] [Related]
58. Isolation and characterization of substance P, substance P 5-11, and substance K from two metastatic ileal carcinoids.
Roth KA; Makk G; Beck O; Faull K; Tatemoto K; Evans CJ; Barchas JD
Regul Pept; 1985 Nov; 12(3):185-99. PubMed ID: 2417286
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
Picard P; Regoli D; Couture R
Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
[TBL] [Abstract][Full Text] [Related]
60. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
